Biotech | January 18, 2022
Cosette Pharma acquires rights to Daiichi Sankyo’s eight branded products
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
Market data indicates that more than twenty percent of the new chemical entities being developed use roller compaction technology in their development and commercialization
The stability is led by healthy demand in the domestic and emerging markets
The TaqMan SARS CoV-2 Mutation Panel is compatible with real-time PCR instruments already commonly used in laboratories around the world
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
During H1 FY2022, the revenues and operating profit margin (OPM) for ICRA sample set showed sharp improvement aided by volume uptick in Covid-19 and allied tests and also demand traction for non-Covid tests
FDA changes inspection classification of the facility to Voluntary Action Indicated
It is a novel oral NLRP3 inflammasome inhibitor
Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions
A single-cell analysis solution that revolutionizes efficiency in drug discovery research by automating the collection of specific cells and intracellular components
Subscribe To Our Newsletter & Stay Updated
